Outcomes of transfemoral transcatheter aortic valve implantation (TAVI) and predictors of thirty-day major adverse cardiovascular events (MACE) and one-year mortality
In: Hellenic Journal of Cardiology, Jg. 62 (2021), Heft 1, S. 57-64
Online
academicJournal
Zugriff:
Objective: TAVI is more frequently used to treat aortic stenosis with the mandate to have a low as possible rate of adverse events. We present our 30-day outcomes and one-year mortality and examine the factors associated with them. Methods: A prospective evaluation was performed of all patients who underwent transfemoral TAVI in Nicosia General Hospital from January 2015 until March 2020. MACE were defined as cardiac death, disabling stroke, and/or major vascular complications (VC). Multiple logistic and Cox regression analyses were used to identify the factors associated with 30-day MACE and one-year mortality, respectively. Results: A total of 235 TAVI procedures were performed (178 balloon-expandable, 57 self-expandable). Thirty-day outcomes were MACE: 4.3%, cardiovascular death: 2.1%, disabling stroke: 1.3%, major VC: 1.7%, and contrast induced nephropathy (CIN): 4.3%. There was a rate of 6.2% new pacemaker implantations and 0.9% of more than mild aortic valve regurgitation (AR) at 30 days. Mortality at one year was 15.1%. The balloon-expandable valves appear to have less new pacemakers, less mild AR, lower contrast volume used, and less days of hospitalization, while the self-expandable valves have lower post-procedural gradients. Low hemoglobulin, history of atrial fibrillation (AF), and lower BMI were predictors of 30-day MACE. Serum creatinine >2 mg/dL, history of AF, RVSP >60 mmHg and major VC are predictors of one-year mortality. Conclusion: We have shown excellent 30-day results with low incidence of adverse events for both the balloon-expandable and self-expandable valves. Clinical factors are the main predictors of both 30-day MACE and one-year mortality; major VC is a strong predictor of one-year mortality.
Titel: |
Outcomes of transfemoral transcatheter aortic valve implantation (TAVI) and predictors of thirty-day major adverse cardiovascular events (MACE) and one-year mortality
|
---|---|
Autor/in / Beteiligte Person: | Eftychiou, Christos ; Eteocleous, Nicolaos ; Zittis, Ioannis ; Simamonian, Krikor ; Ioannou, Antonis ; Loukaidou, Pantelitsa ; Ntaka, Aliki ; Hadjigregoriou, Aris ; Vasiliades, Vasilis ; Adamou, Maria ; Constantinou, Eleni ; Avraamides, Panayiotis |
Link: | |
Zeitschrift: | Hellenic Journal of Cardiology, Jg. 62 (2021), Heft 1, S. 57-64 |
Veröffentlichung: | Elsevier, 2021 |
Medientyp: | academicJournal |
ISSN: | 1109-9666 (print) |
DOI: | 10.1016/j.hjc.2020.09.011 |
Schlagwort: |
|
Sonstiges: |
|